Critical Path Institute is a catalyst in the development of new approaches to advance medical innovation and regulatory science.
We achieve this by leading teams that share data, knowledge, and expertise, resulting in sound, consensus-based science. More…
Upcoming Events
-
Feb 8, 2023 Webinar: TRxA 2023 Funding Opportunities
-
Feb 20, 2023 3rd PSTC Japan Safety Biomarker Workshop
Past Events
-
Jan 21, 2023 - Jan 24, 2023 2023 Critical Care Congress
-
Dec 15, 2022 Register Now: Critical Path to Women Leading in Science
-
Dec 14, 2022 View Now | Shared Stewardship in Collaborative Curation of Rare Disease Datasets
-
Dec 11, 2022 - Dec 14, 2022 15th Annual Conference on the Science of Dissemination and Implementation in Health
Successes
- COA Qualification from FDA for Asthma Daytime Symptom Diary (ADSD) and Asthma Nighttime Symptom Diary (ANSD)
- Qualification of drug-induced kidney injury (DIKI) clinical safety biomarker, composite measure
- COA Qualification from FDA for the Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ)
- C-Path receives COA qualification from FDA for the Symptoms of Major Depressive Disorder Scale (SMDDS)
- C-Path’s PKDOC Secures EMA Qualification Opinion for Enrichment Biomarker in ADPKD
- C-Path’s PKDOC Secures FDA Qualification for Enrichment Biomarker in ADPKD
- Regulatory Support For Autosomal Dominant Polycystic Kidney Disease Biomarker
- C-Path Opportunities Table
- EMA Qualifies ‘Hollow Fiber System’ For Anti-Tuberculosis Drug Development
- FDA and EMA issue first-of-their-kind Letters of Support for two Kidney Biomarkers
News
-
Jan 25, 2023 C-Path Receives Letter of Support from EMA on Duchenne Muscular Dystrophy Clinical Trial Simulation Platform
-
Jan 23, 2023 C-Path and Mobilise-D Collaborate to Improve Impact on the Organizations’ Common Goals
-
Dec 20, 2022 C-Path’s Transplant Therapeutics Consortium Receives EMA Qualification Opinion for iBox Scoring System
-
Dec 20, 2022 C-Path Receives Letter of Support from EMA for Parkinson’s Disease Clinical Trial Simulation Platform
-
Dec 16, 2022 eCOA Consortium and PRO Consortium Announce Publication of Two Open Access Articles
-
Dec 8, 2022 ‘Rare Disease Moonshot’ – Scaling-up public-private partnerships to accelerate research into world’s rarest diseases